ERBB2 and breast cancer: gov Identifier: NCT03991260 and ClinicalTrials.gov Identifier:NCT05412446) and 99mTc-ZHER2:41071 (ClinicalTrials.gov Identifier: NCT05203497)performed at the Department of Radionuclide Therapy and Diagnostics of theCancer Research Institute of the Tomsk National Research Medical Center (CRITNRMC) demonstrated that it is possibile to determine HER2/neu status in theprimary tumor [13, 14] and metastatic lymph nodes in BC patients [15].